Please assess the completion status of the following clinical trial:

Trial Title: Pharmacogenetics of SGLT2 Inhibitors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Of Amish descent~* Age 21 or older~* BMI 18-40 kg/m2~Exclusion Criteria:~* Known allergy to canagliflozin~* History of diabetes, random glucose greater than 200 mg/dL, or HbA1c greater than or equal to 6.5%~* Currently taking diuretics, antihypertensive medication, uric acid lowering medications, or other medication that the investigator judges will make interpretation of the results difficult~* Significant debilitating chronic cardiac, hepatic, pulmonary, or renal disease or other diseases that the investigator judges will make interpretation of the results difficult or increase the risk of participation~* Seizure disorder~* Positive urine human chorionic gonadotropin (hCG) test or known pregnancy within 3 months of the start of the study~* Estimated glomerular filtration rate less than 60 mL/min~* Currently breast feeding or breast feeding within 3 month of the start of the study~* Liver function tests greater than 2 times the upper limit of normal~* Hematocrit less than 35%~* Currently symptomatic for urinary tract or yeast infection or history of two or more urinary tract or yeast infections in the past 12 months.~* Abnormal thyroid stimulating hormone (TSH)

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Wild type genotype (Type: ACTIVE_COMPARATOR): Research subjects with wild type genotypes at three candidate genes encoding sodium-dependent glucose transporter-3, sodium-dependent glucose transporter-4, and glucose transporter-9 (abbreviated as SLC5A4, SLC5A9, SLC2A9, respectively) will be studied before and after canagliflozin treatment.
- Nonsense mutation in SLC5A4 (Type: EXPERIMENTAL): Research subjects who are homozygous for nonsense mutation in SLC5A4 (sodium-dependent glucose transporter-3) will be studied before and after canagliflozin treatment.
- Nonsense mutation in SLC5A9 (Type: EXPERIMENTAL): Research subjects who are homozygous for nonsense mutation in SLC5A9 (sodium-dependent glucose transporter-4) will be studied before and after canagliflozin treatment.
- Missense variant in SLC2A9 (Type: EXPERIMENTAL): Research subjects who are homozygous for nonsynonymous variant in glucose transporter-9 (SLC2A9) will be studied before and after canagliflozin treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).